ReviewInnere Medizin (Heidelberg, Germany)2026
[Approach to suspected glomerulonephritis].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glomerulonephritides (GNs) are inflammatory diseases of the glomeruli and may have primary or secondary causes. They frequently present as nephrotic or nephritic syndrome, and sometimes only as asymptomatic proteinuria or glomerular hematuria. Given that clinical presentations overlap and the underlying etiologies are diverse, kidney biopsy remains the gold standard for establishing the diagnosis, classification, and prognosis. Approximately two-thirds of GNs are primary and one-third secondary, for example in the context of collagen vascular diseases, vasculitides, metabolic disorders, or hematologic conditions. Accurate diagnosis relies on thorough history taking as well as urine and blood testing. Indicators of GN include proteinuria, dysmorphic erythrocytes, red blood cell casts, impaired kidney function, or newly developed hypertension. Proteinuria greater than 0.5 g/day or glomerular hematuria should always prompt further evaluation. Definitive diagnosis is obtained by biopsy, while serologic tests are important for identifying secondary forms. Prognosis varies widely. Rapidly progressive GN is a nephrological emergency and requires immediate inpatient evaluation and treatment.
Indexed as
Identifiers
41893913What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.